Brain and CSF Alzheimer’s Biomarkers Are Associated with SERPINE1 Gene Expression
Genes · 12.07.2025 · 16 (7) · 818
DOI: 10.3390/genes16070818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 12.07.2025. Verfasst von Cynthia Picard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Douglas Mental Health University Institute, Montréal, QC H4H 1R3, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, Plasminogen Activator Inhibitor 1, Brain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Fonds de la Recherche en Santé du Québec (FRSQ), the Canadian Institute for Health Research, National Research Council of Canada (NSERC).
Themen: Demenz
Abstract (Originalsprache)
Background
SERPINE1, also known as plasminogen activator inhibitor (PAI), has been proposed as a potential blood biomarker for the early detection and diagnosis of Alzheimer’s disease (AD). Expanding on previous studies, this research contrasted SERPINE1 levels in CSF and brain tissue of AD patients and those at risk for AD with established AD biomarkers.
Methods
Utilizing OLINK and immunoassay methods, CSF SERPINE1 protein levels were quantified across two separate cohorts: PREVENT-AD and ADNI. Microarray and RNAseq were used to measure tissue SERPINE1 mRNA levels in two separate cohorts: the Douglas-Bell Canada Brain Bank and the Mayo Clinic Brain Bank.
Results
At the pre-clinical stage, elevated CSF levels of pTau, tTau and synaptic markers, alongside reduced hippocampal volume, correlate with CSF SERPINE1 levels. Elevated cortical SERPINE1 mRNA levels in autopsy-confirmed AD show weak correlation with regional plaques and tangles densities, but strong correlation with Braak staging.
Conclusions
CSF SERPINE1 levels can be used as an early biomarker for the detection of pathological changes associated with AD. Higher SERPINE1 levels correlate more strongly with tau pathology than with amyloid formation or deposition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Douglas Mental Health University Institute, Montréal, QC H4H 1R3, Canada.
- Centre for the Studies on Prevention of Alzheimer's Disease, Montréal, QC H4H 1R3, Canada.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, SE-405 30 Gothenburg, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 431 30 Mölndal, Sweden.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.
- UK Dementia Research Institute at UCL, London WC1E 6BT, UK.
ORCID-Profile: Cynthia Picard, Judes Poirier
Förderung
- CIHR
- Fonds de la Recherche en Santé du Québec (FRSQ), the Canadian Institute for Health Research
- National Research Council of Canada (NSERC)
- J.L. Levesque Foundation and Brain Canada
- FRQS, the CIHR
- Brain Canada
- Swedish Research Council
- European Union’s Horizon Europe research and innovation programme
Zitieren
APA
Picard, C., Zetterberg, H., Blennow, K., Villeneuve, S., Poirier, J., & On Behalf Of The Prevent-Ad Research Group (2025). Brain and CSF Alzheimer’s Biomarkers Are Associated with SERPINE1 Gene Expression. Genes, 16(7), 818. https://doi.org/10.3390/genes16070818
Vancouver
Picard C, Zetterberg H, Blennow K, Villeneuve S, Poirier J, On Behalf Of The Prevent-Ad Research Group. Brain and CSF Alzheimer’s Biomarkers Are Associated with SERPINE1 Gene Expression. Genes. 2025;16(7):818. doi:10.3390/genes16070818
BibTeX
@article{Picard2025,
author = {Picard, Cynthia and Zetterberg, Henrik and Blennow, Kaj and Villeneuve, Sylvia and Poirier, Judes and On Behalf Of The Prevent-Ad Research Group},
title = {Brain and CSF Alzheimer’s Biomarkers Are Associated with SERPINE1 Gene Expression},
journal = {Genes},
year = {2025},
volume = {16},
number = {7},
pages = {818},
doi = {10.3390/genes16070818}
}
EUVIMED